IMPE Abstracts

Background: Pediatric growth hormone deficiency (pGHD) is treated with daily somatropin (recombinant human growth hormone) injections. High discontinuation rates and poor adherence to treatment, which may be associated with worse growth outcomes, have been documented in Japan, EU and the US.Objectives: To describe adherence to daily somatropin treatment and assess the association between adherence and height velocity (HV...

LUM-201 (ibutamoren), an agonist of the growth hormone (GH) Secretagogue Receptor 1a (GHSR1a), is an investigational oral GH secretagogue currently in three iPGHD Phase 2 trials. A LUM-201 predictive enrichment marker (PEM) may be used to select previously diagnosed iPGHD patients likely to respond to LUM-201. PEM positivity is defined as baseline insulin-like growth factor-1 (IGF-1) level >30 ng/mL and a peak GH of ≥ 5 ng/mL in response to a single 0.8 mg/kg oral dose o...